<DOC>
	<DOCNO>NCT02674581</DOCNO>
	<brief_summary>An oral dose healthy renally impaired subject determine drug effect BMS-663068 .</brief_summary>
	<brief_title>A Study Pharmacokinetics Safety BMS-663068 Administered Subjects With Normal Renal Function With Mild , Moderate , Severe End Stage Renal Dysfunction</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Inclusion Criteria ( For renal impaired subject ) : Classification renal function base eGFR Clinical , ECG , laboratory finding consistent renal dysfunction BMI 18.0 38.0 kg/m2 inclusive Women child bear potential ( WOCBP ) sexually active fertile men partner WOCBP must use nonhormonal highly effective birth control Slightly different inclusion criterion define protocol healthy subject History uncontrolled unstable cardiovascular , respiratory , hepatic , gastrointestinal , endocrine , hematopoietic , psychiatric , and/or neurological disease within 6 month screen Evidence rapidly deteriorate renal function , define screen eGFR decrease previous eGFR â‰¥ 50 % within last 3 month Current recent ( within 3 month study drug administration ) clinically significant gastrointestinal disease gastrointestinal surgery ( include cholecystectomy ) could impact absorption study drug Any major surgery within 4 week study drug administration . Other protocol define exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>